Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31273564 | 0.88 | GNAO1 (0.51) | GNAO1HRH3DRD2CHRM2CHRM4 | |
| SCHEMBL31273549 | 0.88 | GNAO1 (0.51) | GNAO1HRH3DRD2CHRM2CHRM4 | |
| SCHEMBL13110276 | 0.86 | DRD2 (0.40) | GNAO1HRH3DRD2DRD4DRD3 | |
| SCHEMBL25700795 | 0.86 | GNAO1 (0.50) | GNAO1HRH3DRD2EPHX1EPHX2 | |
| SCHEMBL14380398 | 0.86 | GNAO1 (0.59) | GNAO1HRH3DRD2CHRM2CHRM4 | |
| SCHEMBL5197870 | 0.86 | GNAO1 (0.54) | GNAO1HRH3DRD2CHRM2CHRM4 | |
| SCHEMBL24207822 | 0.85 | GNAO1 (0.53) | GNAO1HRH3DRD2CHRM2CHRM4 | |
| SCHEMBL14393786 | 0.85 | CYP1A2 (0.46) | GNAO1HRH3DRD2CHRM2CHRM4 | |
| SCHEMBL7321853 | 0.85 | GNAO1 (0.45) | GNAO1HRH3DRD2CHRM2CHRM4 | |
| SCHEMBL6445015 | 0.85 | GNAO1 (0.45) | GNAO1HRH3DRD2EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023218187-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | UNIVERSITY OF DUNDEE (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-4276097-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | University Of Dundee (GB) | 2023-11-15 | — | — | EP | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2022268052-A9 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023137034-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022268052-A1 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20170029457-A1 | METHODS FOR THE SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2017-02-02 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | GNAO1 3832/4885HRH3 3390/4885DRD2 4409/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885HRH3 3631/4885DRD2 4346/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885HRH3 3631/4885DRD2 4346/4885 |
| US-20170029457-A1 | METHODS FOR THE SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS | RNGTT, NUDT1, NSUN3 | GNAO1 2121/4885HRH3 1487/4885DRD2 4656/4885 |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | GNAO1 1808/4885HRH3 3622/4885DRD2 4701/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | GNAO1 1122/4885HRH3 4581/4885DRD2 4080/4885 |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | GNAO1 2920/4885HRH3 788/4885DRD2 1842/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | GNAO1 2920/4885HRH3 788/4885DRD2 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.